Home › Funds › PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE › DMAC
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE position in DMAC
DIAMEDICA THERAPEUTICS INC · Health Care
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE reported holding 875,000 shares of DMAC (DIAMEDICA THERAPEUTICS INC) in its Q1 2026 13F filing — a position valued at US$5.9M, representing 8.05% of its reported portfolio and ranking #4 among its reported holdings. PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE has disclosed DMAC holdings in 10 of the last 11 reported quarters, going back to Q3 2023.
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
How PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE's DMAC position evolved
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE first disclosed a stake in DMAC in Q3 2023 at 470,000 shares (US$1.2M). The position peaked in Q4 2025 at 875,000 shares, worth US$7.0M. Across 10 filings, PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE increased the stake 5 time(s), trimmed it 1 time(s) and left it unchanged 3 time(s). The most recent filing (Q1 2026) shows 875,000 shares valued at US$5.9M. Notable position changes include a 35% increase in Q3 2025 (shares rose 16% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 470.00K | $1.21M | New |
| Q4 2023 | 500.00K | $1.42M | Add |
| Q1 2024 | 500.00K | $1.39M | Hold |
| Q3 2024 | 482.61K | $2.02M | Reduce |
| Q4 2024 | 514.78K | $2.80M | Add |
| Q1 2025 | 600.00K | $2.27M | Add |
| Q2 2025 | 650.00K | $2.54M | Add |
| Q3 2025 | 875.00K | $6.01M | Add |
| Q4 2025 | 875.00K | $6.96M | Hold |
| Q1 2026 | 875.00K | $5.92M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DMAC and 13F data
DMAC (DIAMEDICA THERAPEUTICS INC) is a Health Care company. 47 other funds we track also report a position in DMAC — the largest reported positions include COOPERMAN LEON G (US$24.3M), Bleichroeder LP (US$2.7M), MEMBERS WEALTH LLC (US$810K). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DMAC
- COOPERMAN LEON G 3.45M sh · $24.29M · Q2 2026
- Bleichroeder LP 382.32K sh · $2.69M · Q2 2026
- MEMBERS WEALTH LLC 101.38K sh · $810.04K · Q3 2026
- COBALT CAPITAL MANAGEMENT, INC. 90.00K sh · $633.60K · Q2 2026
More on PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE
FAQ
How long has PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE held DMAC?
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE has disclosed DMAC holdings in 10 of the last 11 reported quarters, going back to Q3 2023.
What is PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE's current position in DMAC?
As of Q1 2026, PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE holds 875.00K shares of DMAC (DIAMEDICA THERAPEUTICS INC), valued at $5.92M, representing 8.05% of its reported portfolio and ranking #4.
Has PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE been buying or selling DMAC?
In the latest 13F filing (Q1 2026), PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE held unchanged its position in DMAC. The position peaked in Q4 2025 at 875.00K shares.
Which other funds hold DMAC?
Other major institutional holders of DMAC include COOPERMAN LEON G, Bleichroeder LP, MEMBERS WEALTH LLC, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.